Researchers Receive Grants From National Comprehensive Cancer Network Oncology Research Program Funded Through Boehringer Ingelheim Corporation

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded five research grants to investigators following NCCN ORP Scientific Review Committee analysis of proposals submitted in response to the NCCN Afatinib Request for Proposals. These grants were made possible through a $2-million research grant from Boehringer Ingelheim Pharmaceuticals, Inc. to scientifically evaluate and define the clinical effectiveness of afatinib (BIBW 2992) in solid tumors, including breast, non-small cell lung (NSCLC), and head and neck cancers.

Back to news